Ionis Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
549300SI4ZGLG0BLUZ92 - ISIN
US4622221004 (IONS )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. Read full profile
Fundamentals
- Net revenue
€805.39M - Gross margin
98.9% - EBIT
-€227.33M - EBIT margin
-28.2% - Net income
-€228.78M - Net margin
-28.4%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Baroldi Joseph | EVP, Chief Business Officer |
|
|
|
|
| BENNETT C FRANK | EVP, Chief Scientific Officer |
|
|
|
|
| Devers Shannon L. | EVP, Chief Human Resources Ofc |
|
|
|
|
| KLEIN JOSEPH III | N/A |
|
|
|
|
| LOSCALZO JOSEPH | N/A |
|
|
|
|
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| John D. Spears |
|
|
|
Sell |
| Cathie Wood |
|
|
|
Sell |
| Peter Brown |
|
|
|
Sell |